C5orf4, designated as Fatty Acid Hydroxylase Domain Containing 2 (FAXDC2), represents a pivotal component within the cellular lipid metabolism framework, specifically involved in the hydroxylation of fatty acids. This enzymatic process is integral for the biosynthesis of complex lipids, which are crucial for various cellular functions including membrane fluidity, signal transduction, and the modulation of inflammatory processes. The precise role of C5orf4 in these pathways suggests that its activity directly impacts the composition and functionality of cellular lipids, thereby influencing key cellular processes and metabolic pathways. Inhibition of C5orf4, therefore, has the ability to significantly alter lipid profiles within the cell, affecting not only the structural components of membranes but also the myriad signaling pathways that rely on specific lipid molecules.
Mechanisms of C5orf4 inhibition could involve a range of molecular interactions and regulatory pathways, encompassing direct binding by specific inhibitors that block the enzyme's active site, to more complex regulatory feedback mechanisms that control its expression and activity at the transcriptional or post-translational level. Given the enzyme's role in fatty acid metabolism, inhibitors might include small molecule compounds that mimic its natural substrates or products, thereby competitively inhibiting its enzymatic function. Alternatively, regulatory proteins that interact with C5orf4 could modulate its activity through mechanisms such as allosteric inhibition or the modification of its expression in response to changes in cellular lipid levels or metabolic states. Furthermore, the inhibition of upstream pathways that supply substrates or co-factors required for C5orf4's activity could indirectly reduce its function, highlighting the interconnectedness of metabolic pathways in regulating enzyme activity. Understanding the inhibition mechanisms of C5orf4 is crucial for elucidating the complex network of lipid metabolism and its implications in cellular physiology and pathologies associated with dysregulated lipid synthesis and modification.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D intercalates into DNA and inhibits RNA synthesis, thereby blocking transcription. This can lead to reduced protein expression. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide blocks the translocation step in protein synthesis, thereby inhibiting translation and protein production. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
α-Amanitin inhibits RNA polymerase II, which is responsible for mRNA synthesis, thereby reducing protein expression. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine inhibits DNA methyltransferases, leading to DNA demethylation. This can alter gene expression patterns, potentially reducing protein expression. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
TSA is a histone deacetylase inhibitor. By inhibiting HDACs, TSA increases acetylation of histones, potentially leading to altered gene expression and reduced protein production. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Suberoylanilide Hydroxamic Acid (Vorinostat) inhibits histone deacetylases, which can lead to increased acetylation of histones. This can alter gene expression patterns, potentially reducing protein expression. | ||||||
Puromycin | 53-79-2 | sc-205821 sc-205821A | 10 mg 25 mg | $166.00 $322.00 | 436 | |
Puromycin causes premature chain termination during translation, leading to the production of non-functional peptides and reduced protein synthesis. | ||||||
Rifampicin | 13292-46-1 | sc-200910 sc-200910A sc-200910B sc-200910C | 1 g 5 g 100 g 250 g | $97.00 $328.00 $676.00 $1467.00 | 6 | |
Rifampicin inhibits DNA-dependent RNA polymerase in prokaryotic organisms, thereby reducing RNA and subsequent protein synthesis. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $43.00 $189.00 $316.00 $663.00 | 6 | |
DRB inhibits RNA polymerase II, leading to reduced transcription and subsequent protein expression. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
Fluorouracil (5-FU) is a nucleotide analog that inhibits RNA synthesis. This can lead to reduced transcription and protein expression. | ||||||